Mouse Monoclonal AURKA Antibody

Aurora Kinase A (AURKA) is a serine/threonine kinase critical for regulating mitotic progression, particularly during the G2/M phase transition, centrosome maturation, spindle assembly, and chromosomal segregation. It is encoded by the *AURKA* gene and is part of the Aurora kinase family, which includes AURKB and AURKC. Dysregulation of AURKA is frequently linked to cancer, as its overexpression promotes genomic instability, tumorigenesis, and metastasis by disrupting cell cycle checkpoints and enhancing oncogenic signaling pathways. AURKA antibodies are essential tools in research and diagnostics, enabling the detection and quantification of AURKA protein expression in cells and tissues. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study AURKA's role in cancer biology, therapeutic response, and as a potential biomarker. Clinically, AURKA overexpression correlates with poor prognosis in cancers such as breast, ovarian, and colorectal carcinomas. Inhibitors targeting AURKA (e.g., Alisertib) are under investigation in clinical trials, further driving demand for reliable antibodies to assess target engagement and pharmacodynamic effects. However, challenges remain in ensuring antibody specificity due to structural similarities among Aurora kinase isoforms. Validated AURKA antibodies are crucial for elucidating its dual role as both an oncogene and a regulator of cellular homeostasis, supporting advances in precision oncology and drug development.